Teva Pharmaceutical announced the exclusive launch of generic Viread (tenofovir disoproxil fumarate) tablets 300 mg in the U.S.
Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older. Additionally, tenofovir disoproxil fumarate tablets are an HBV reverse transcriptase inhibitor, indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
“Currently, 1.1 million people in the U.S are living with HIV2 and an estimated 850,000 to 2.2 million have chronic hepatitis B virus infection,3 said Brendan O’Grady, Executive Vice President, North America Commercial at Teva. “The launch of generic Viread is an important addition to our portfolio; but, more importantly, it brings an effective, affordable treatment option to these patients in an area that’s lacking.”
With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Viread had annual sales of approximately $762 million in the U.S., according to IMS data as of October 2017.
Tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older.